Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples
暂无分享,去创建一个
Brendan A. Larder | Stuart Bloor | Margriet Van Houtte | Kurt Hertogs | Schlomo Staszewski | Rudi Pauwels | Veronica Miller | K. Hertogs | R. Pauwels | B. Larder | S. Kemp | S. Bloor | S. Staszewski | V. Miller | T. Alcorn | Sharon D. Kemp | Timothy M. Alcorn | Christel Van den Eynde | C. V. D. Eynde | M. V. Houtte
[1] J. Falloon,et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.
[2] B. Larder,et al. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.
[3] P. Harrigan,et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. , 1999, AIDS.
[4] T. Merigan,et al. Multiple Concurrent Reverse Transcriptase and Protease Mutations and Multidrug Resistance of HIV-1 Isolates from Heavily Treated Patients , 1998, Annals of Internal Medicine.
[5] J. Condra,et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.
[6] M. Markowitz,et al. Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors , 1998, Antimicrobial Agents and Chemotherapy.
[7] B. Larder,et al. Mutations in Retroviral Genes Associated with Drug Resistance , 1996 .
[8] D. Ho,et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir , 1996, Nature Medicine.
[9] H. Vahaboğlu,et al. Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.
[10] C. Debouck,et al. The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.
[11] G. Moyle,et al. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. , 1998, Expert opinion on investigational drugs.
[12] W. Greene,et al. The molecular biology of human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.
[13] R. Hogg,et al. The antiviral effect of ritonavir and saquinavir incombination amongst HIV‐infected adults: results from a community‐based study , 1998, AIDS.
[14] Brendan Larder,et al. A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.
[15] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[16] D. R. Kuritzkes,et al. Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir , 1998, Antimicrobial Agents and Chemotherapy.
[17] J. Mellors,et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.
[18] J. Weber,et al. Emergence of resistant variants of HIV in vivo during monotherapy with the proteinase inhibitor saquinavir. , 1997, The Journal of antimicrobial chemotherapy.
[19] D. Ho,et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease , 1996, Antimicrobial agents and chemotherapy.